Triple-Negative Breast Cancer: Adjuvant Therapeutic Options

Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast cancers. Patients with TNBC generally experience a mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gucalp, Ayca, Traina, Tiffany A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265248/
https://www.ncbi.nlm.nih.gov/pubmed/22312556
http://dx.doi.org/10.1155/2011/696208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265248/
https://www.ncbi.nlm.nih.gov/pubmed/22312556
http://dx.doi.org/10.1155/2011/696208

Ejemplares similares